TransTech Digest: Why Mitochondria Matter
Article By:
Patrick Cox
Read
Sunday, November 2, 2014 1:49 PM EDT
We’re beginning to understand how the "mitochondrial network" fails as we age and how this failure impacts many areas of health.
Teva Beats Q3 Earnings Expectations, Updates Outlook
Article By:
Zacks Investment Research
Read
Friday, October 31, 2014 5:52 PM EDT
Third quarter revenues remained flat at $5.058 billion, slightly below the Zacks Consensus Estimate of $5.100 billion.
In this article: TEVA
Active Stocks: ABBV, DRAD, ZIOP, AEGR, SRPT
Article By:
BioMedReports
Read
Friday, October 31, 2014 5:36 PM EDT
U.S. stocks surged Friday, with the Dow hitting an intraday record, joining a rally in Asian and European shares that was spurred by the Bank of Japan’s decision to unexpectedly expand its stimulus measures.
Could The Bulls Run Into Year-End?
Article By:
Chris Ciovacco
Read
Thursday, October 30, 2014 8:59 PM EDT
As noted in detail on May 14, it is always important to understand both the bullish and bearish case for stocks. While the headline number for Thursday’s GDP report was impressive, the report contained something that may keep the Fed in a market-friendly mode.
Bristol-Myers Immunotherapy Drug Impresses With Phase 2 Lung Cancer Data
Article By:
Terry Chrisomalis
Read
Thursday, October 30, 2014 8:22 PM EDT
Bristol-Myers posts outstanding results In lung cancer data using immunotherapy drug
In this article: BMY
Some Indicators Work At Tops – Others At Bottoms
Article By:
Blair Jensen
Read
Wednesday, October 29, 2014 10:05 PM EDT
I had the honor of being on a panel with JC Parets, Chris Kimble, Ryan Detrick, and Charlie Bilello at Stocktoberfest this year. They are a great group of guys with a wealth of information that should be in everyone’s daily must read list.
From This Day Forward, We Will Watch How The Stock Market Performs Without The Fed’s Monetary Heroin
Article By:
Michael Snyder
Read
Wednesday, October 29, 2014 8:28 PM EDT
From this day forward, we will be looking to see how the stock market performs without the help that the Federal Reserve has been providing.
Newsmakers: Gilead, Amedisys, Compugen, ICAD, Cara Therapeutics
Article By:
BioMedReports
Read
Wednesday, October 29, 2014 4:08 PM EDT
U.S. stocks dipped and bonds slid after the Federal Reserve offered a brighter assessment of the U.S. job market, a shift that investors reckoned could bring forward the timing of interest-rate increases.
When Searching For A Value Leader, Fear Is Also An Option
Article By:
Global Economic Intersection
Read
Tuesday, October 28, 2014 9:23 PM EDT
The market has rebounded sharply since finding support at the 1820 to 1825 area and we have witnessed some signs of capitulation selling recently.
Here’s The Wonder Drug That Will Quadruple Gilead’s 3rd Quarter Profits
Article By:
Leigh Drogen
Read
Tuesday, October 28, 2014 10:40 AM EDT
Gilead Sciences is set to report earnings for its 3rd quarter of 2014 after the market closes on Tuesday October 28.
In this article: GILD
Pfizer Beats Earnings, But Lacks Year-Over-Year EPS Growth
Article By:
Zacks Investment Research
Read
Tuesday, October 28, 2014 9:43 AM EDT
PFE posted stronger than expected quarterly results, helped by growing sales of its cancer drugs and increase in demand in emerging markets.
Novavax To Launch Clinical Trial Of Ebola Vaccine; Sarepta Announces Update On Eteplirsen
Article By:
BioMedReports
Read
Tuesday, October 28, 2014 4:14 AM EDT
Novavax, Inc. will launch a Phase 1 clinical trial of an Ebola vaccine candidate in December.